MO

Michael OLLMANN

EX Exelixis: 5 patents #65 of 312Top 25%
AM Amgen: 2 patents #1,289 of 2,867Top 45%
Overall (All Time): #705,475 of 4,157,543Top 20%
7
Patents All Time

Issued Patents All Time

Patent #TitleCo-InventorsDate
11732266 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof Yang Li, Jun Zhang, Oliver HOMANN, Leslie P. Miranda, Justin K. MURRAY +5 more 2023-08-22
10870856 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof Yang Li, Jun Zhang, Oliver HOMANN, Leslie P. Miranda, Justin K. MURRAY +4 more 2020-12-22
8758994 CDK9 as modifier of the IGF pathway and methods of use Mark E. Maxwell, Timothy S. Heuer, Lynn Margaret Bjerke 2014-06-24
8288119 PGDS as modifiers of the PTEN pathway and methods of use Chunyan Song, Lynn Margaret Bjerke 2012-10-16
7927872 ALDOs as modifiers of the IGF pathway and methods of use Mark E. Maxwell, Timothy S. Heuer, Benjamin C. Hitz 2011-04-19
6630297 Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target Kevin Patrick Keegan, Thomas Stout, David Matthews, Alison Joly 2003-10-07
6515109 Human ECT2 polypeptide Kevin Patrick Keegan, Thomas Stout, David Matthews, Alison Joly 2003-02-04